The Hidden Mystery Behind Radiopharmaceutical Market

The Hidden Mystery Behind Radiopharmaceutical Market

The Global Radiopharmaceutical Market by geography into – North America, South America, Europe, Asia-Pacific (APAC), and Middle East and Africa

2021-06-11

Increasing Number of Pet and Spect Scans

The widespread availability of SPECT and PET scanning machines will result in a growing number of radio diagnostic and radio therapeutics events globally. For instance, the number of PET scanning machines installed per head in North America is more compared to that installed in Europe, thus leading to an increased usage of radiotracers in the region. 

PET and SPECT are modern scanning systems used to detect and treat various conditions including cancer, cardiovascular diseases, and other neurology-related diseases 

Single-photon emission computed tomography (SPECT) using technetium-99m (Tc-99m) tracer technology accounts for 80% of all nuclear medicine procedures worldwide. While making up around 50% of the global market, the United States (US) was solely dependent on international sources for Tc-99 m's parent isotope, molybdenum-99 (Mo-99 or moly), until recently.

In the field of oncology, the PET (positron emission tomography) uses FDG (18 Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, as it demonstrates the increased metabolism by malignant cells when compared to that of normal cells.

According to the American Nuclear Society, 90% of the radioisotopes are used in gamma cameras or PET scan nuclear diagnostics. The remaining 10% are used in radioactive therapeutics drugs to treat diseases such as cancer, heart disease, gastrointestinal, endocrine, neurological disorders, etc.

The volume of PET procedures in the United States is approximately two million per Year. There are about 2,670 PET scanners in hospitals across the U.S. that collectively perform about 2 million scans per year.

Oncology accounts for more than 80% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 5% each. According to the National Oncology PET Registry, about 84% of the slightly more than 1,600 PET facilities in the United States have PET/CT systems.

In 2018, the number of PET and PET/CT scans performed in the U.S. is estimated at 2.093 million. This is a net increase of about 8% in just the last year. These scans were performed at approximately 2,500 sites using fixed PET, PET/CT, or PET/MR scanners or mobile PET services.

In 2017, an estimated 1.9600 million clinical PET and PET/CT scans were performed in the US, a 14.2% increase in use compared to 2015. In 2015, it is estimated that over 1.7852 million clinical PET and PET/CT patient scans will be performed in U.S hospitals and non-hospital locations in the United States.

Alternative Diagnostic Radiopharmaceuticals Solutions

SPECT and PET are the most advanced diagnostic systems used for the treatment of cancer, cardiovascular disease, neurological disorders, etc. The introduction of new radioisotopes lead to the development of new diagnostic imaging systems which helps to identify new diseases that cannot be identified through alternative diagnostic systems. 

For example, the IBA group has developed cargo X-ray systems, E-beam, Rhodotron, and Dynamitron imaging systems for the diagnosis of several diseases 

According to Health Technology Assessment 2016, clinical trial studies on TRAPEZE represented the clinical efficacy of chemotherapy with zoledronic acid, strontium-89, in the treatment of bone metastatic castration-refractory prostate cancer. 

Another therapy called molecular radiotherapy (MRT) is a modality of treatment, wherein unsealed radioactive sources are delivered systemically to a patient

Lutetium 177: 

Iodine-131, a therapeutic radiotracer continues to be an ideal tracer for the treatment of not only thyroid cancer but also other therapeutic indications and is being slowly replaced by Lutetium-177 (Lu-177). Lu-177, a low-energy β-particle emitter is identified to be one of the emerging radiotracers for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) and neuroendocrine tumors. 

For instance, Advanced Accelerator Applications is currently developing three Lu-177-based radio therapeutics, Lutathera- a drug for the treatment of neuroendocrine tumors, 177LU PSMA-R2- for the treatment of prostate cancer, and 177LU-NEOBOMB1 for the treatment of gastrointestinal stromal tumors, prostate and breast cancer. The company is expected to launch Lutathera or lutetium Lu 177 dotatate by next year thus representing a huge market opportunity in the global radiotherapeutics market.

Furthermore, Lu-177-based molecules DOTATOC and JR- 11, respectively being developed by ITG (Germany) and Ipsen (France) are also expected to enter the radiopharmaceutical market as therapeutic drugs in the next few years for similar indications. 

However, all of these molecules are linked with 68Ga-labeled analog as they can form an ideal partnership in the development of theranostics. Promising prostate cancer therapies based on antibodies (ATL-101 from ATLAB Pharma, France) or the PSMA analogs labeled with Lu=177 are also expected to hit the market in the market over the coming years

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com

Found it interesting?

Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866

We have 5000+ marketing reports and serve across 130+ countries

Tags:

#radiopharmaceuticalmarket,